Skip to main content

Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study.

Publication ,  Journal Article
Kamalian, A; Ho, SG; Patel, M; Lewis, A; Bakker, A; Albert, M; O'Brien, RJ; Moghekar, A; Lutz, MW
Published in: Biomolecules
July 8, 2023

(1) Background: Despite the existence of well-established, CSF-based biomarkers such as amyloid-β and phosphorylated-tau, the pathways involved in the pathophysiology of Alzheimer's disease (AD) remain an active area of research. (2) Methods: We measured 3072 proteins in CSF samples of AD-biomarker positive mild cognitive impairment (MCI) participants (n = 38) and controls (n = 48), using the Explore panel of the Olink proximity extension assay (PEA). We performed group comparisons, association studies with diagnosis, age, and APOE ε4 status, overrepresentation analysis (ORA), and gene set enrichment analysis (GSEA) to determine differentially expressed proteins and dysregulated pathways. (3) Results: GSEA results demonstrated an enrichment of granulocyte-related and chemotactic pathways (core enrichment proteins: ITGB2, ITGAM, ICAM1, SELL, SELP, C5, IL1A). Moreover, some of the well-replicated, differentially expressed proteins in CSF included: ITGAM, ITGB2, C1QA, TREM2, GFAP, NEFL, MMP-10, and a novel tau-related marker, SCRN1. (4) Conclusion: Our results highlight the upregulation of neuroinflammatory pathways, especially chemotactic and granulocyte recruitment in CSF of early AD patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Biomolecules

DOI

EISSN

2218-273X

Publication Date

July 8, 2023

Volume

13

Issue

7

Location

Switzerland

Related Subject Headings

  • tau Proteins
  • Proteomics
  • Pilot Projects
  • Peptide Fragments
  • Nerve Tissue Proteins
  • Humans
  • Cognitive Dysfunction
  • Biomarkers
  • Amyloid beta-Peptides
  • Alzheimer Disease
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kamalian, A., Ho, S. G., Patel, M., Lewis, A., Bakker, A., Albert, M., … Lutz, M. W. (2023). Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study. Biomolecules, 13(7). https://doi.org/10.3390/biom13071094
Kamalian, Aida, Sara G. Ho, Megha Patel, Alexandria Lewis, Arnold Bakker, Marilyn Albert, Richard J. O’Brien, Abhay Moghekar, and Michael W. Lutz. “Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study.Biomolecules 13, no. 7 (July 8, 2023). https://doi.org/10.3390/biom13071094.
Kamalian A, Ho SG, Patel M, Lewis A, Bakker A, Albert M, et al. Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study. Biomolecules. 2023 Jul 8;13(7).
Kamalian, Aida, et al. “Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study.Biomolecules, vol. 13, no. 7, July 2023. Pubmed, doi:10.3390/biom13071094.
Kamalian A, Ho SG, Patel M, Lewis A, Bakker A, Albert M, O’Brien RJ, Moghekar A, Lutz MW. Exploratory Assessment of Proteomic Network Changes in Cerebrospinal Fluid of Mild Cognitive Impairment Patients: A Pilot Study. Biomolecules. 2023 Jul 8;13(7).

Published In

Biomolecules

DOI

EISSN

2218-273X

Publication Date

July 8, 2023

Volume

13

Issue

7

Location

Switzerland

Related Subject Headings

  • tau Proteins
  • Proteomics
  • Pilot Projects
  • Peptide Fragments
  • Nerve Tissue Proteins
  • Humans
  • Cognitive Dysfunction
  • Biomarkers
  • Amyloid beta-Peptides
  • Alzheimer Disease